Antisense Therapeutics Limited EBIT

Antisense Therapeutics Limited (ATHJF) currently reports a EBIT of $-23M as of June 2024. That compares with $-12M in the prior-year period — down 87.1% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Antisense Therapeutics Limited's EBIT history and peer comparisons.

Antisense Therapeutics Limited's EBIT decreased from $-12M to $-23M — a 87.1% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Antisense Therapeutics Limited's EBIT of $-23M is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Antisense Therapeutics Limited reported $-23M in EBIT as of June 2024. That compares with $-12M in the prior-year period — down 87.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-23M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Antisense Therapeutics Limited, and consider following ATHJF for alerts when major investors trade the stock.